Bauer Ann-Kathrin, Marquardt Iris, Sundermann Benedikt, Wolf Christine, Raupach Katrin, Grundmann-Hauser Kathrin, Gieldon Laura, Otterbach Maximilian, Maurer Martin, Haack Tobias, Lee-Kirsch Min Ae, Korenke Georg-Christoph, Hitz Marc-Phillip
Institute of Medical Genetics, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany.
Department of Neuropediatrics, University Children's Hospital, Klinikum Oldenburg, Oldenburg, Germany.
Front Immunol. 2025 Jul 18;16:1453496. doi: 10.3389/fimmu.2025.1453496. eCollection 2025.
Heterozygous pathogenic variants in have been associated with dyschromatosis symmetrica hereditaria, while biallelic pathogenic variants have been associated with Aicardi-Goutières syndrome 6 (AGS6). However, the heterozygous variant c.3019G>A, (p.Gly1007Arg) has been described to cause neurological manifestations, which resemble AGS6 and are associated with an upregulation of interferon-stimulated genes. We report a four-generation family with two symptomatic family members and five unaffected carriers of the heterozygous pathogenic variant c.3019G>A. The index (patient 1) manifested a gait disorder at three years of age (weakness in his legs, a tendency to fall and hyperreflexia), dyslalia, and mild cognitive developmental delay. A paternal half-brother (patient 4) to patient´s father (patient 2) presented with irritability and regression of previous skills at the age of 6 months after a fever reaction, following the second routine hexavalent vaccination at the age of 4 months. At 20 years of age, the patient was wheelchair-bound, had spasticity and severe global development delay. A blood test in both patients showed increased interferon signature with activation of type 1-interferon. Five asymptomatic carriers were identified in this family (age range 2-81 years of age) nearly all of them (except the 81-year old patient) showed a strong activation of type 1 interferon response in peripheral blood. Affected individuals had higher interferon signature than asymptomatic, underlining the possible role of interferon activation in disease mechanism. To our knowledge, this is the biggest family reported to date, encompassing a wide age-range of carriers, including an asymptotic carrier of advanced age (81 years of age).
杂合致病性变异已与对称性遗传性色素沉着异常相关,而双等位基因致病性变异则与Aicardi-Goutières综合征6型(AGS6)相关。然而,杂合变异c.3019G>A(p.Gly1007Arg)已被描述可导致神经学表现,其类似于AGS6且与干扰素刺激基因的上调有关。我们报告了一个四代家族,其中有两名有症状的家族成员以及五名杂合致病性变异c.3019G>A的未受影响携带者。先证者(患者1)在三岁时出现步态障碍(腿部无力、易摔倒及反射亢进)、构音障碍和轻度认知发育迟缓。患者父亲(患者2)的同父异母兄弟(患者4)在4个月时进行第二次常规六价疫苗接种后,于6个月龄发烧反应后出现易怒及之前技能的倒退。20岁时,该患者需依靠轮椅行动,有痉挛及严重的全面发育迟缓。两名患者的血液检测均显示干扰素特征增加且1型干扰素激活。在这个家族中鉴定出五名无症状携带者(年龄范围为2至81岁),几乎所有携带者(除81岁患者外)在外周血中均显示出强烈的1型干扰素反应激活。受影响个体的干扰素特征高于无症状个体,这突出了干扰素激活在疾病机制中的可能作用。据我们所知,这是迄今为止报道的最大的家族,涵盖了广泛年龄范围的携带者,包括一名高龄(81岁)的无症状携带者。